Compare XRAY & COAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XRAY | COAG |
|---|---|---|
| Founded | 1899 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | 2009 | 2026 |
| Metric | XRAY | COAG |
|---|---|---|
| Price | $8.74 | $31.06 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 5 |
| Target Price | $13.73 | ★ $61.20 |
| AVG Volume (30 Days) | ★ 4.1M | 355.5K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.81% | N/A |
| EPS Growth | ★ 33.04 | N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.47 | N/A |
| P/E Ratio | $64.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.90 | $27.47 |
| 52 Week High | $14.73 | $55.42 |
| Indicator | XRAY | COAG |
|---|---|---|
| Relative Strength Index (RSI) | 28.67 | 21.88 |
| Support Level | N/A | $29.54 |
| Resistance Level | $10.66 | $38.87 |
| Average True Range (ATR) | 0.36 | 2.57 |
| MACD | -0.05 | -0.79 |
| Stochastic Oscillator | 5.69 | 1.10 |
Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (dental consumables and lab products) and Sirona Dental Systems (technologically advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantology. It distributes two-thirds of its dental consumables, technology, and equipment through third-party distributors. The remaining portfolio is sold to labs and offices through the firm's salesforce or directly to consumers.
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.